Injection targets double chin fat without surgery
NCT ID NCT07677683
First seen Jul 01, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This phase 2 study tests an investigational drug called STP705, given as injections under the chin, to reduce submental fat (double chin). Healthy adults aged 18 to 65 with moderate to severe submental fullness receive up to three treatment sessions over two months. The study evaluates how well the injections reduce fat and checks for safety and tolerability at three different dose levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- STP705
- What this could lead to
- If successful, this could offer a non-surgical option for reducing submental fat (double chin) with a simple injection procedure.
- What could go wrong
- This is an early phase 2 study with only 30 participants, so results may not apply broadly. Side effects like injection site reactions are possible, and the treatment may not produce noticeable fat reduction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBMENTAL FULLNESS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emeritus Research Sydney
RECRUITINGSydney, New South Wales, 2019, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.